Infliximab Dose Rounding Pratices in Pediatric Inflammatory Bowel Disease

Authors

Kelly C. Sandberg, Wright State UniversityFollow
Benjamin H. Shpeen
Sally J. Eder
Muhammad Dhanani
Sarah J. Clark
Gary L. Freed
Jeremy Adler

Document Type

Conference Proceeding

Publication Date

10-2012

Abstract

Infliximab (IFX) is commonly used to treat Inflammatory Bowel Disease (IBD). IFX is supplied in 100mg vials and remains expensive. Dosing usually starts at 5mg/kg, and is commonly rounded up or down. The scope of dosing practices is unknown. Under-dosing may place patients at risk for exacerbation of IBD. Over-treatment potentially carries increased risk of infectious and malignant complications. We aimed to characterize IFX dosing practices among pediatric IBD practitioners participating in the ImproveCareNow Network.

Comments

The link is to a list of abstracts from the conference proceedings

Repository Citation

Sandberg, K. C., Shpeen, B. H., Eder, S. J., Dhanani, M., Clark, S. J., Freed, G. L., & Adler, J. (2012). Infliximab Dose Rounding Pratices in Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 55 (Suppl 1), 215, E69.
https://corescholar.libraries.wright.edu/pediatrics/488